People: Alexion Pharmaceuticals, Inc. (ALXN.O)

ALXN.O on Nasdaq

46.91USD
9 Feb 2010
Price Change (% chg)

$0.94 (+2.04%)
Prev Close
$46.91
Open
--
Day's High
$47.02
Day's Low
$46.10
Volume
446,628
Avg. Vol
683,671
52-wk High
$49.57
52-wk Low
$30.78

view people for:

Summary

Name Age Since Current Position
Link, Max 68 2002 Chairman of the Board
Bell, Leonard 51 2002 Chief Executive Officer, Secretary, Treasurer, Director
Sinha, Vikas 45 2005 Chief Financial Officer, Senior Vice President
Squinto, Stephen 52 2007 Executive Vice President, Head - Research and Development
Rother, Russell 48 2008 Senior Vice President, Chief Scientific Officer
Dubin, Thomas 46 2005 Senior Vice President, General Counsel
Coissac, Patrice 60 2005 Senior Vice President, General Manager; President of Alexion Europe SAS
Hooks, M. Stacy 41 2008 Senior Vice President - Technical Operations
Hallal, David 42 2008 Senior Vice President - Commercial Operations, Americas
Bedrosian, Camille 55 2008 Senior Vice President, Chief Medical Officer
Nicaise, Claude 56 2008 Senior Vice President - Strategic Development and Global Regulatory Affairs
Caron, Daniel 45 2008 Vice President - Site Operations and Engineering
Melrose, Glenn 53 2007 Vice President - Human Resources
Madri, Joseph 62 1992 Director
Parven, Alvin 68 1999 Director
Norby, R. Douglas 73 1999 Director
Mathis, Larry 65 2004 Director
Waeger, Ruedi 65 2005 Director
Keller, William 2009 Director
» Insider Trading

Biographies

Name Description
Link, Max Max Link, Ph.D. has been the Chairman of the Board of Directors of Alexion Pharmaceuticals since December 2002 and a director of Alexion since April 1992. From March 2001 to September 2003, Dr. Link was Chairman of the Board and CEO of Centerpulse AG, a medical implant company. From May 1993 to June 1994, Dr. Link was Chief Executive Officer of Corange (Bermuda), the parent company of Boehringer Mannheim Therapeutics, Boehringer Mannheim Diagnostics and DePuy Orthopedics. From 1992 to 1993, Dr. Link was Chairman of the Board of Sandoz Pharma, Ltd., a manufacturer of pharmaceutical products. From 1987 to 1992, Dr. Link was the Chief Executive Officer of Sandoz Pharma and a member of the Executive Board of Sandoz, Ltd., Basel. Prior to 1987, Dr. Link served in various capacities with the United States operations of Sandoz, including as President and Chief Executive Officer. Dr. Link is the chairman of the board of directors of CytRx Corporation, and Celsion Corporation, and is also a director of Discovery Labs, Inc., each a publicly held pharmaceutical and/or life-science company. Dr. Link holds a Ph.D. in economics from University of St. Gallen (Switzerland).
Bell, Leonard Leonard Bell is Chief Executive Officer, Secretary, Treasurer, Director of Alexion Pharmaceuticals Inc. He is the principal founder of Alexion, and has been a director of Alexion since February 1992, and the company’s President (until April 2002, when such title was transferred), Chief Executive Officer, Secretary and Treasurer. From 1991 to 1992, Dr. Bell was an Assistant Professor of Medicine and Pathology and co-Director of the program in Vascular Biology at the Yale University School of Medicine. From 1990 to 1992, Dr. Bell was an attending physician at the Yale-New Haven Hospital and an Assistant Professor in the Department of Internal Medicine at the Yale University School of Medicine. Dr. Bell was a recipient of the Physician Scientist Award from the National Institutes of Health and Grant-in-Aid from the American Heart Association as well as various honors and awards from academic and professional organizations. His work has resulted in more than 20 scientific publications and 9 patent applications. Dr. Bell was also a director of The Medicines Company from May 2000 until April 2005. Dr. Bell received his A.B. from Brown University and M.D. from Yale University School of Medicine. Dr. Bell is currently an Adjunct Assistant Professor of Medicine and Pathology at Yale University School of Medicine.
Sinha, Vikas Vikas Sinha joined Alexion Pharmaceuticals Inc as Senior Vice President and Chief Financial Officer in September 2005. From June 1994 to August 2005, Mr. Sinha held various positions with Bayer AG in the United States, Japan, Germany, and Canada, most recently serving since February 2001 as Vice President and Chief Financial Officer of Bayer Pharmaceuticals Corporation, USA. Mr. Sinha has been responsible for financial and business risk management, strategic planning, contracting, customer services, information systems, and supply chain and site administration in North America. Mr. Sinha was also a member of the Pharmaceutical Management Committee for North America. Prior to his appointment in the United States, Mr. Sinha was Vice President and Chief Financial Officer of Bayer Yakuhin Ltd., in Japan and Manager, Mergers and Acquisitions with Bayer AG in Germany. He began his career at Bayer in Toronto as part of an executive development program in the healthcare division. Prior to Bayer, Mr. Sinha held several positions of increasing responsibilities with ANZ Bank and Citibank in South Asia. Mr. Sinha holds a Masters of Business Administration from the Asian Institute of Management which included an exchange program with the University of Western Ontario (Richard Ivey School of Business). He is also a qualified Chartered Accountant from the Institute of Chartered Accountants of India.
Squinto, Stephen Stephen P. Squinto is a founder of Alexion Pharmaceuticals Inc and has been Executive Vice President and Head of Research and Development since June 2007. He held the position of Executive Vice President and Head of Research between August 2000 and June 2007. He also held the positions of Senior Vice President and Chief Technical Officer from March 1998 to July 2000, Vice President of Research, Molecular Sciences, from August 1994 to March 1998, Senior Director of Molecular Sciences from July 1993 to July 1994, and Director of Molecular Development from 1992 to July 1993. From 1989 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. most recently serving as Senior Scientist and Assistant Head of the Discovery Group. From 1986 to 1989, Dr. Squinto was an Assistant Professor of Biochemistry and Molecular Biology at Louisiana State University Medical Center and an Adjunct Professor of Neuroscience at the Tulane University Medical School. Dr. Squinto’s work has led to over 70 scientific papers in the fields of gene regulation, growth factor biology and gene transfer. Dr. Squinto’s work is primarily in the fields of molecular and cellular biology. Dr. Squinto served as a Director of the Biotechnology Research and Development Corporation, a biotechnology consortium, from 1997 to 2003. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.
Rother, Russell Russell P. Rother is Senior Vice President, Chief Scientific Officer of Alexion Pharmaceuticals Inc. He has been Chief Scientific Officer since January 2008, Senior Vice President, Research from 2005 to 2008, Vice President, Discovery Research from 2001 to 2005, Senior Director of Discovery Research from 1999 to 2001, Director of Gene Technologies from 1996 to 1999, Senior Staff Scientist from 1994 to 1996 and Staff Scientist from 1992 to 1994. As one of the original scientists at Alexion, Dr. Rother played a critical role in the engineering and development of Alexion’s current antibody therapeutics and continues to lead discovery efforts in the identification of new indications and targets. Dr. Rother was a leader in the initiation of the paroxysmal nocturnal hemoglobinuria (PNH) program and played a major role in its development and approval. Prior to 1992, Dr. Rother was a Postdoctoral Research Fellow in the Department of Immunobiology at Yale University School of Medicine. Dr. Rother’s work has led to over 50 scientific papers and patents in the fields of hematology, complement biology, transplantation, autoimmunity, and gene therapy. Dr. Rother received a B.S. in Biology from Southwestern Oklahoma State University and a Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center in conjunction with the Oklahoma Medical Research Foundation.
Dubin, Thomas Thomas I.H. Dubin has been Senior Vice President and General Counsel of Alexion Pharmaceuticals Inc since August 2005. He was Vice President and General Counsel from January 2001 to July 2005. From February 1999 to September 2000 he served as Vice President, General Counsel and Secretary for ChiRex Inc., a NASDAQ-traded international corporation providing advanced process development services and specialty manufacturing to the pharmaceutical industry, which in September 2000 was acquired by and merged into Rhodia. From 1992 to 1999, Mr. Dubin held various positions with Warner-Lambert Company, including Assistant General Counsel, Pharmaceuticals. Prior to his tenure with Warner-Lambert, Mr. Dubin was a corporate attorney for five years with Cravath, Swaine & Moore in New York. Mr. Dubin received his J.D. from New York University and his B.A., cum laude, from Amherst College.
Coissac, Patrice Patrice Coissac joined Alexion Pharmaceuticals Inc as Corpoprate Senior Vice President, General Manager and President of Alexion Europe SAS in November 2005. Mr. Coissac has a broad international background in the pharmaceutical industry. In 2004-2005, he founded and ran his own consulting firm to serve biopharmaceutical companies in their strategic development. From 1999 to mid 2003, when Pharmacia was acquired by Pfizer, Mr. Coissac served as President of Pharmacia SAS France and was responsible for the integration of Monsanto (Searle) with Pharmacia & Upjohn in France. Prior to joining Pharmacia, Mr. Coissac held several managerial positions at pharmaceutical companies including Head of Operations for Novartis Belgium and President of Boehringer Mannheim Therapeutics France. Mr. Coissac also served as Marketing Senior Vice President for global pharmaceutical operations at Corange International and previously held several global marketing positions in Sandoz Pharmaceuticals in Tokyo, Japan where he was posted during several years, in Switzerland in Sandoz World Headquarters and in France at the beginning of his career.
Hooks, M. Stacy M. Stacy Hooks has been Senior Vice President of Technical Operations of Alexion Pharmaceuticals Inc since July 2008, Vice President of Manufacturing and Technical Services from July 2006 to July 2008, Executive Director, Manufacturing and Technical Services from August 2004 to July 2006, Senior Director, Manufacturing and Technical Services from January 2004 to August 2004, and Director of Quality Control from December 2002 to January 2004. Dr. Hooks is responsible for managing the development, manufacturing, process validation, quality and testing of products. From 2001 to 2002, Dr. Hooks was a Director of Quality Assurance at Pharmacia, Inc. From 2000 to 2001, Dr. Hooks was the Director of Quality at QIAGEN, Inc., a multinational life sciences company. From 1996 to 2000 Dr. Hooks was employed at MedImmune, Inc., a biopharmaceutical firm, in increasing roles of responsibility, most recently as the Associate Director of Quality Control. Prior to MedImmune Dr. Hooks was employed at Biogen-IDEC. Dr. Hooks received his B.S. in Chemistry from Murray State University and a Ph.D. in Chemistry from Emory University.
Hallal, David David L. Hallal has been Senior Vice President, Commercial Operations, Americas of Alexion Pharmaceuticals Inc since November 2008. He was Senior Vice President, US Commercial Operations from November 2007 until November 2008. Prior to that, Mr. Hallal was Vice President, US Commercial Operations from June 2006 until November 2007. Mr. Hallal is responsible for all Commercial Functions in the U.S., Canada, and Latin America, including marketing, sales, and reimbursement/access. Prior to Alexion, from April 2004 to June 2006, Mr. Hallal was Vice President of Sales at OSI Eyetech where he led the U.S. launch of the first-in-class anti-VEGF therapy, Macugen for age-related macular degeneration. From August 2002 to February 2004, Mr. Hallal was Senior Director of Sales for Biogen Idec’s Immunology Sales Team, where he built a sales organization dedicated to the launch of the first-in-class biologic Amevive for psoriasis. For more than ten years starting in 1992, Mr. Hallal held various leadership positions at Amgen, focusing on Epogen®, Neupogen®, Neulasta® and Aranesp® in the hematology and oncology marketplace. More specifically from April 1999 to August 2002, he served as the Southeast Oncology Sales Director and Oncology Health Systems Sales Director. From 1998 to 1999, Mr. Hallal served as Amgen’s Director of Oncology National Accounts. From 1992 to 1998, Mr. Hallal served in roles of escalating responsibility for the promotion of Epogen and Neupogen, including National Account Manager where he was responsible for forging relationships with managed care organizations in the U.S. He holds a B.A. from the University of New Hampshire.
Bedrosian, Camille Camille L. Bedrosian has served as Senior Vice President and Chief Medical Officer of Alexion Pharmaceuticals Inc since May 2008. From 2002 to 2008, Dr. Bedrosian served as Chief Medical Officer for ARIAD Pharmaceuticals, Inc., a biotechnology company developing small molecules for oncology patients, in Cambridge, MA. From 1997 to 2002, Dr. Bedrosian served in the Clinical Research and Development Department of Genetics Institute, Inc., which became part of Wyeth, and assumed roles of increasing responsibility including Senior Director, Oncology/Hematology and Therapeutic Area Director for Hemophilia. From 1986 to 1997, she was a Fellow, an Associate, and then Assistant Professor of Medicine in the Division of Hematology and Oncology at Duke University Medical Center and the Duke Comprehensive Cancer Center. Dr. Bedrosian received her B.A. degree from Harvard University/Radcliffe College in Chemistry, her M.S. in Biophysics from M.I.T., and her M.D. from Harvard Medical School.
Nicaise, Claude Claude Nicaise joined Alexion Pharmaceuticals Inc as Senior Vice President of Strategic development and Global Regulatory Affairs in July 2008. Since 1983, and until joining Alexion, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including the following senior management positions: Vice-President of Global Development, Vice-President Worldwide Regulatory Science and Strategy, and Oncology, Infectious Disease and NeuroScience. Dr. Nicaise received his medical degree from the Universite libre de Bruxelles in Belgium.
Caron, Daniel Daniel N. Caron has been Vice President, Site Operations and Engineering of Alexion Pharmaceuticals Inc since July 2008. After joining the Company in 1992, Mr. Caron was Operations Manager from 1992 to 1993, Senior Operations Manager from 1993 to 1996, Director of Operations from 1996 to 1998, and Senior Director, Operations and Engineering from 1998 to 2004 and Executive Director, Operations and Engineering from 2004 to 2008. Mr. Caron has been responsible for managing the engineering, build-out, and operations of the Company’s research, manufacturing, and administrative facilities. Prior to 1992, Mr. Caron was a research scientist at Imclone Systems, Inc., a biopharmaceutical firm. Mr. Caron received his B.A. in Biology, from Adelphi University and M.S. in Biomedical Engineering from Polytechnic University of New York.
Melrose, Glenn Glenn Melrose joined Alexion Pharmaceuticals Inc as Vice President, Human Resources in July 2007 after serving in the same position at NPS Pharmaceuticals, Inc. from June 2005. He joined Amersham in 1998 where he held various positions of increasing responsibility in sales and marketing, before rising to the position of Vice President, Human Resources, North America, ultimately the worldwide Human Resources function for Amersham Biosciences in 2003 and 2004. Mr. Melrose received a B.S. in Biology from Washington and Lee University and an M.S. in Experimental Biology from the University of Maryland. He began his career as a scientist at the University of Maryland Cancer Center and Becton Dickinson before joining Amersham Diagnostics in 1988.
Madri, Joseph Joseph A. Madri, Ph.D., M.D. is a founder of Alexion Pharmaceuticals and has been a Director since February 1992. Since 1980, Dr. Madri has been on the faculty of the Yale University School of Medicine and is currently a Professor of Pathology. Dr. Madri serves on the editorial boards of numerous scientific journals and he is the author of over 234 scientific publications. Dr. Madri works in the areas of regulation of angiogenesis, vascular cell-matrix interactions, cell-cell interactions, lymphocyte-endothelial cell interactions and endothelial and smooth muscle cell biology and neural stem biology, and has been awarded a Merit award from the National Institutes of Health. Dr. Madri received his B.S. and M.S. in Biology from St. John’s University and M.D. and Ph.D. in Biological Chemistry from Indiana University.
Parven, Alvin Alvin S. Parven has been a Director of Alexion Pharmaceuticals since May 1999. Since 1997, Mr. Parven has been President of ASP Associates, a management and strategic consulting firm. From 1994 to 1997, Mr. Parven was Vice President at Aetna Business Consulting, reporting to the Office of the Chairman of Aetna. From 1987 to 1994, Mr. Parven was Vice President, Operations at Aetna Health Plans. Prior to 1987, he served in various capacities at Aetna including Vice President, Pension Services from 1983 to 1987. Mr. Parven received his B.A. from Northeastern University.
Norby, R. Douglas R. Douglas Norby has been a Director of Alexion Pharmaceuticals since September 1999. Since July 2003 and until January 31, 2006, Mr. Norby has been Sr. Vice-President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging. From March 2002 to February 2003, Mr. Norby served as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. From December 2000 to March 2002, Mr. Norby served as Senior Vice President and Chief Financial Officer of Novalux, Inc., a manufacturer of lasers for optical networks. From 1996 until December 2000, Mr. Norby served as Executive Vice President and Chief Financial Officer of LSI Logic Corporation, a semiconductor company, and he has also served as a director of LSI Logic Corporation since 1993. From July 1993 until November 1996, he served as Senior Vice President and Chief Financial Officer of Mentor Graphics Corporation, a software company. Mr. Norby served as President of Pharmetrix Corporation, a drug delivery company, from July 1992 to September 1993, and from 1985 to 1992, he was President and Chief Operating Officer of Lucasfilm, Ltd., an entertainment company. From 1979 to 1985, Mr. Norby was Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company. Mr. Norby is a director of STATS Chip PAC, Ltd., a semi-conductor company, NEXX Systems, Inc., a semiconductor manufacturing equipment company, Neterion, Inc., a communications device company, and Intellon Corporation, a semiconductor company. Mr. Norby received a B.A. in Economics from Harvard University and an M.B.A. from Harvard Business School.
Mathis, Larry Larry L. Mathis has been a Director of Alexion Pharmaceuticals since March 2004. Since 1998, Mr. Mathis has served as an executive consultant with D. Petersen & Associates providing counsel to select clients on leadership, management, governance, and strategy. For the 27 years prior to joining D. Petersen & Associates, Mr. Mathis served in various capacities within The Methodist Hospital System, in Houston, Texas – an organization comprising 16 corporations and 37 hospital affiliates in the U.S. and abroad. From 1997 to 1998, Mr. Mathis served as a consultant to the Chairman of the Board of The Methodist Hospital System. Prior to that, he was President and Chief Executive Officer, as well as a member of the Board of Directors, from 1983 to 1997. Mr. Mathis received a Master’s degree in Health Administration from Washington University in St. Louis, and a Bachelor of Arts in Social Sciences from Pittsburg State University in Kansas.
Waeger, Ruedi Ruedi E. Waeger, Ph.D. has been a Director of Alexion Pharmaceuticals since March 2005. Dr. Waeger has spent the past 30 years in the pharmaceutical and therapeutic protein industry. Most recently, he was President and Chief Executive Officer of Aventis Behring L.L.C., a global plasma therapeutics product business which was acquired by CSL Ltd in 2004 to form ZLB Behring. While at Aventis Behring, Dr. Waeger played a key role in guiding the company as it refined its product pipeline and extensive manufacturing facilities. Dr. Waeger became the head of Aventis Behring following the merger of the owners of Centeon L.L.C., a leader in plasma proteins, where Dr. Waeger was Chief Executive Officer. Prior thereto, Dr. Waeger was President and Chief Executive Officer of ZLB Central Laboratories, Blood Transfusion Service of Swiss Red Cross, and before that spent more than 20 years at Sandoz Ltd., where he had consecutive worldwide responsibilities for Strategic Research and Development Planning, Human Resource Management, and Marketing, including responsibility for three global product launches. Dr. Waeger currently sits on the Board of Talecris Biotherapeutics, Inc. He earned a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology.
Keller, William Mr. William R. Keller has been appointed as Director of Alexion Pharmaceuticals, Inc. Currently, Mr. Keller is the General Manager of Keller Pharma Consultancy, a pharmaceutical consulting firm he founded in China. He is also a senior consultant to the Shanghai Foreign Investment Development Board, and serves as the Deputy General Manager of Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd. From 1976 to 2003, Mr. Keller held various positions with Roche Group in Asia and South America. For the last ten of these years, he was the General Manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd., where he played a key role in the development of the overall Roche strategy and in the leadership of its business operations in China. Mr. Keller is the Honorary President of the R&D-based Pharmaceutical Association, and the Vice Chairman of the Shanghai Association of Foreign Investment Enterprises. He is an Honorary Citizen of Shanghai. Mr. Keller graduated from the School of Economics and Business Administration (Zurich). He will serve as a member of the Compensation Committee and the Nominating and Governance Committee of Alexion's Board of Directors.

Options Compensation

Name Options Value
Link, Max 0 0
Bell, Leonard 712,262 9,223,487
Sinha, Vikas 20,000 647,074
Squinto, Stephen 262,654 3,906,533
Rother, Russell 0 0
Dubin, Thomas 161,000 1,610,039
Coissac, Patrice 0 0
Hooks, M. Stacy 0 0
Hallal, David 0 0
Bedrosian, Camille 0 0
Nicaise, Claude 0 0
Caron, Daniel 0 0
Melrose, Glenn 0 0
Madri, Joseph 0 0
Parven, Alvin 0 0
Norby, R. Douglas 0 0
Mathis, Larry 0 0
Waeger, Ruedi 0 0
Keller, William 0 0

Insider Trading

Name Shares Traded Price
NORBY ROCKFORD DOUGLAS 3,965 $0.00
DUBIN THOMAS IH 6,000 $0.00
MADRI JOSEPH A 3,965 $0.00
SQUINTO STEPHEN P 9,000 $0.00
MATHIS LARRY 3,965 $0.00
KELLER WILLIAM R 3,965 $0.00
HALLAL DAVID 6,000 $0.00
LINK MAX E 3,965 $0.00
SINHA VIKAS 8,000 $0.00
BELL LEONARD 22,000 $0.00
WAEGER RUEDI E 3,965 $0.00
COISSAC PATRICE 6,000 $0.00
PARVEN ALVIN S 3,965 $0.00
DUBIN THOMAS IH 249 $47.22
SQUINTO STEPHEN P 332 $47.22
LINK MAX E 4,000 $42.06
HALLAL DAVID 227 $47.22
BELL LEONARD 1,294 $47.22
SINHA VIKAS 539 $47.22
DUBIN THOMAS IH 1,382 $47.68
SQUINTO STEPHEN P 1,465 $47.67
HALLAL DAVID 1,088 $47.78
SINHA VIKAS 2,861 $47.68
BELL LEONARD 5,522 $47.79
BELL LEONARD 22,710 $48.22
» Full list on Insider Trading
view people for: